In addition to increased GSAP levels observed in AD mouse models (Chu et al., 2015), GSAP up-regulation has also been reported in neurodegenerative contexts such as Down’s syndrome (Chu et al., 2016), which is obligately associated with Aβ plaque pathology due to triplication of human chromosome 21 harboring APP (Wiseman et al., 2015). The gene discussed is GSAP; the disease is Down syndrome.